THE ROLE OF PHARMACISTS IN EVALUATING AND INTERVENING THE PATIENTS WITH DIABETIC NEUROPATHY

  • Sesilia Andriani Keban Faculty of Pharmacy, Pancasila University
  • Syamsudin Abdillah Faculty of Pharmacy, Pancasila University
  • Najuah Najuah Postgraduate of Hospital Pharmacy, Faculty of Pharmacy, Pancasila University, Jakarta, Indonesia

Abstract

Diabetic neuropathies is the presence of and/or signs of peripheral nerve dysfunctions in people with diabetes after the exclusion of other causes. The purpose of this study was to estimate the prevalence and risk factors for diabetic peripheral neuropathy, to evaluate the score of neuropathy, and also to determine the effect of pharmacist intervention towards diabetic neuropathy patients at Gatot Soebroto Hospital Jakarta in 2013. Data about socio-demographic characters, age, duration of diabetic, blood glucose, blood pressure, cardiovascular diseases, lifestyle BMI and smoking were collected. Pharmacist intervention was given to increase patient information about diabetic neuropathy and its risks factors. There were 59 respondents involved in this study. It can be found that 15.3% respondents had mild diabetic peripheral neuropathy, 1.7% had moderate diabetic peripheral neuropathy, 1.7% had severe diabetic peripheral neuropathy, and as much as  81,4% respondents had no neuropathy. There was a correlation (but not statistically significant) between diabetic peripheral neuropathy and its' risks factors such as ages, duration of diabetes, sex, cardiovascular disease (hypertension, cardiac disease)and lifestyle(smoking habit and body mass index). Pharmacist intervention showed an increase on the patients knowledge about diabetic neuropathy and also a significant decrease on the patient's blood glucose level (P˂0,05).

Keywords : diabetic neuropathy, pharmacist role, prevalence, score, risk factors, blood glucose.

References

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35 Suppl 1:S64-71.
2. King H, Aubert RE, Herman WH. Global burden of diabetes,
1995-2025: Prevalence, numerical estimates, and projections. Diabetes
Care 1998;21(9):1414-31.
3. American Diabetes Association. Standards of medical care in diabetes
2013. Diabetes Care 2013;36 Suppl 1:S11-66.
4. National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2011.
5. Tesfaye S. Epidemiology and etiology of diabetic peripheral neuropathies. Adv Stud Med 2004;4(10G):S1014-21.
6. Feldman EL, Vincent A. Review the prevalence, impact, and multifactorial pathogenesis of diabetic peripheral neuropathy. Adv Stud Med 2004;4(8A):S642-9.
7. Morkrid K. The Prevalence of and Risk Factors for Diabetic Peripheral
Neuropathy Among Type 2 Diabetic Outpatients in Bangladesh.

University of Oslo, Faculty of Medicine, Norway. 2007. Available from: https://www.duo.uio.no/bitstream/handle/10852/30151/69091. pdf? sequence=1. [Last accessed on 2016 Jan 08].
8. Oguejiofor OC, Odenigbo CU, Oguejiofor CB. Evaluation of the effect of duration of diabetes mellitus on peripheral neuropathy using the United Kingdom screening test scoring system, bio-thessiometry and aesthesiometry. Niger J Clin Pract 2007;13(3):240-7.
9. Cornblath DR. Diabetic neuropathy - diagnostic methods. Adv Stud
Med 2004;4:8A.
10. Bril V, Perkins B, Toth C. Neuropathy: Clinical practice guidelines expert committee. Can J Diabetes 2013;37:S142-4.
11. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes
2008;32 Suppl 1:S140-41, S199-201.
12. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in Type 1 diabetic patients. Diabetes Care 2005;28(7):1649-55.
13. Feldman EL. Etiology of diabetic microvascular disease and scientific rationale for new therapeutic targets. Adv Stud Med 2005;5(3A):S138-43.

14. Navale AM, Paranjape AN. Role of inflammation in development of diabetic complications and commonly used inflammatory markers with respect to diabetic complications. Int J Pharm Pharm Sci
2013;5 Suppl 2:1-15.
15. Rampello L, Vecchio I, Malaguarnera G. Diabetic neuropathy diagnosis.
Acta Med Mediterr 2012;28:133-8.
16. Bril V, Perkins BA. Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care 2002;25(11):2048-52.
17. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: Consensus recomendations on diagnosis, assesment and management. Diabetes Metab Res Rev 2011;27(7):629-38.
18. Bril V, Tomioka S, Buchanan RA, Perkins BA. Complications reliability and validity of the modified Toronto clinical neuropathy score in diabetic sensorimotor polyneuropathy. Diabet Med 2009;26(3):240-6.
19. Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug counseling by pharmacist, diabetic disease booklet and special medication containers on glycemic control of Type 2 diabetes mellitus: A randomized controlled trial. J Med Assoc Thai 2005;88 Suppl 4:S134-41.
Statistics
266 Views | 332 Downloads
How to Cite
Keban, S. A., S. Abdillah, and N. Najuah. “THE ROLE OF PHARMACISTS IN EVALUATING AND INTERVENING THE PATIENTS WITH DIABETIC NEUROPATHY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 2, Feb. 2017, pp. 127-31, doi:10.22159/ajpcr.2017.v10i2.14796.
Section
Original Article(s)